Hence, maintenance of adequate RPL3 level seems to be crucial for anticancer therapeutic success, i.e., in response of p53-mutated lung cancer cells that acquired drug resistance (Russo et al. 2017). This evidence concerns the gene RPL3 and lung carcinoma.